Core Insights - Abbott Laboratories (ABT) has a market cap of $218.8 billion and is recognized as a global healthcare leader with a diverse portfolio that includes medical devices, diagnostics, nutrition, and branded generic pharmaceuticals [1] - The company is particularly noted for its innovations in chronic disease management and specialized nutrition [1] Stock Performance - Over the past year, ABT shares have increased by 5.8%, underperforming the S&P 500 Index, which rose by 17.5% [2] - Year-to-date, ABT stock has gained 10.1%, compared to a 15.6% increase in the S&P 500 [2] - Abbott has outperformed the Health Care Select Sector SPDR Fund (XLV), which saw a 1.5% decrease over the past 52 weeks [3] Q3 FY2025 Results - For Q3 FY2025, Abbott reported revenue of $11.37 billion, reflecting a year-over-year increase of 6.9%, but it fell short of Wall Street expectations [4] - Adjusted EPS rose by 7.4% to $1.30, meeting market expectations [4] - The company reaffirmed its full-year 2025 outlook, maintaining organic sales growth guidance of 7.5%–8.0% (excluding COVID-related testing) and 6.0%–7.0% (including it) [4] Earnings Forecast - Analysts project ABT's EPS to grow by 10.3% year-over-year to $5.15 for the fiscal year ending in December 2025 [5] - Abbott has a strong earnings surprise history, having met or exceeded consensus estimates in the last four quarters [5] - The consensus rating among 29 analysts is a "Strong Buy," with 20 "Strong Buy" ratings, two "Moderate Buys," and seven "Holds" [5] Analyst Ratings - The current analyst sentiment is more bullish than a month ago, with 19 analysts previously advising a "Strong Buy" [6] - On October 17, Citi analyst Joanne Wuensch reaffirmed her "Buy" rating on Abbott Laboratories, and Benchmark Co. analyst Bruce Jackson also issued a "Buy" rating on the same day [6]